CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 18 enrolled
Drug / intervention
Gluten powder 4gdietary
Likely dose
Gluten powder 4gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04054544
NCT04054544Early Ph 1Completed
CompareCT.gov

A Gluten Challenge Study to Characterize Peripheral Blood and Intestinal Gluten-specific CD4+ T Cell Subsets in Patients With Celiac Disease

Merck Sharp & Dohme LLC·interventional·Posted Aug 13, 2019·Updated Mar 6, 2023

In Brief

A Early Phase 1 clinical trial evaluating Gluten powder 4g for Celiac Disease. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedAug 13, 2019
Enrollment StartAug 28, 2020
Primary CompletionJun 23, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.9 years ago

Interventions

Gluten powder 4gdietary

Gluten powder 4g oral BID